Neurogene Stock (NASDAQ:NGNE)

Forecast Ownership Financials Chart

Previous Close

$21.26

52W Range

$6.88 - $37.27

50D Avg

$26.23

200D Avg

$19.78

Market Cap

$324.04M

Avg Vol (3M)

$230.88K

Beta

1.63

Div Yield

-

NGNE Company Profile

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

107

IPO Date

Mar 07, 2014

Website

NGNE Performance

NGNE Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-82.61M	$-55.58M	$-56.52M
Net Income	$-75.14M	$-36.32M	$-55.19M
EBITDA	$-82.61M	$-52.29M	$-51.99M
Basic EPS	-	$-2.83	$-4.30
Diluted EPS	-	$-2.83	$-4.30

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
FULC	Fulcrum Therapeutics, Inc.
PRTC	PureTech Health plc
AUTL	Autolus Therapeutics plc
QSI	Quantum-Si incorporated
ADCT	ADC Therapeutics S.A.
SLDB	Solid Biosciences Inc.
OCGN	Ocugen, Inc.
ALMS	Alumis Inc. Common Stock
BNTC	Benitec Biopharma Inc.